Different Biomarker Modalities and Response to Anti-PD-1/PD-L1 Therapies-Reply

Affiliations

¹ Department of Dermatology, Johns Hopkins Medical Institutions, Baltimore, Maryland.
² Division of Biostatistics & Bioinformatics at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Medical Institutions, Baltimore, Maryland.

Comment

Steve Lu et al. JAMA Oncol. 2020.

. 2020 Feb 1;6(2):299.

doi: 10.1001/jamaoncol.2019.5154.

¹ Department of Dermatology, Johns Hopkins Medical Institutions, Baltimore, Maryland.
² Division of Biostatistics & Bioinformatics at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Medical Institutions, Baltimore, Maryland.

No abstract available

Comment on

Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade: A Systematic Review and Meta-analysis.
Lu S, Stein JE, Rimm DL, Wang DW, Bell JM, Johnson DB, Sosman JA, Schalper KA, Anders RA, Wang H, Hoyt C, Pardoll DM, Danilova L, Taube JM. Lu S, et al. JAMA Oncol. 2019 Aug 1;5(8):1195-1204. doi: 10.1001/jamaoncol.2019.1549. JAMA Oncol. 2019. PMID: 31318407 Free PMC article.
Different Biomarker Modalities and Response to Anti-PD-1/PD-L1 Therapies.
Liu S, Niu W. Liu S, et al. JAMA Oncol. 2020 Feb 1;6(2):298-299. doi: 10.1001/jamaoncol.2019.5148. JAMA Oncol. 2020. PMID: 31774455 No abstract available.